Immatics skips interim anzu-cel analysis and adds 90 patients ahead of pivotal 2027 verdict

Immatics N.V. is putting more patients and more capital behind its pivotal anzu-cel melanoma program while keeping the most important regulatory catalyst on schedule for the first half of 2027. The biotechnology company plans to expand its randomized SUPRAME Phase 3 trial by approximately 90 patients to roughly 450 participants, primarily to increase statistical power for overall survival, while replacing previously planned interim and final progression-free survival analyses with one streamlined final PFS assessment. The change follows slower-than-modeled accumulation of progression and death events across the blinded trial and recent feedback from the United States Food and Drug Administration. Crucially for investors, Immatics N.V. says the larger enrollment will not delay the final PFS analysis or its planned 2027 Biologics License Application submission.

The company has the financial capacity to absorb the larger study. Cash, cash equivalents and other financial assets totaled $448.2 million at June 30, 2026, compared with $534.7 million at the end of 2025, while management continues to project a cash runway into 2028. That balance gives Immatics N.V. room not only to complete the enlarged SUPRAME study but also to continue building commercial infrastructure for anzu-cel and fund a broader PRAME pipeline spanning additional cell therapies and T-cell receptor bispecifics.

Adding 90 patients could strengthen anzu-cel’s commercial case without delaying the decisive PFS result

SUPRAME is evaluating anzu-cel, formally known as anzutresgene autoleucel and previously called IMA203, against investigator’s choice in patients with unresectable or metastatic melanoma who previously received a PD-1 immune checkpoint inhibitor. The global randomized trial is enrolling patients in North America and Europe and is designed to serve as an adequate and well-controlled study supporting full regulatory approval if successful. Its primary endpoint is blinded independent central review-assessed progression-free survival under RECIST 1.1, with overall survival, objective response rate, safety and quality-of-life measures among the principal secondary endpoints.

Immatics N.V. had originally planned both interim and final PFS analyses after predetermined numbers of progression or death events occurred. Aggregate events are now accumulating more slowly than the company initially modeled, leading management to replace those two analyses with a single final assessment based on a lower prespecified number of PFS events. The revised structure will retain 90% statistical power for the primary endpoint, while required randomizations supporting the PFS analysis are still expected to be completed by the end of 2026.

The additional enrollment serves a different purpose. Immatics N.V. intends to add approximately 90 patients, taking total SUPRAME enrollment to about 450, to strengthen statistical power around overall survival and potentially produce a more compelling long-term product profile. Management specifically said that the higher number of OS events required under the revised design will not affect the timing of the final PFS analysis expected during the first half of 2027.

That distinction matters commercially. PFS could determine whether SUPRAME succeeds as the registration-enabling trial, but stronger overall-survival evidence could influence physicians, payers and treatment guidelines after approval. An individualized T-cell therapy must justify manufacturing complexity, treatment-center requirements and associated costs against existing melanoma treatments, making durable survival evidence potentially valuable even when it is not the primary endpoint.

Slower progression events may look encouraging but remain impossible to attribute while SUPRAME stays blinded

The slower event rate will inevitably attract investor attention because an event in SUPRAME means either disease progression or death. However, the trial remains blinded, so there is currently no evidence establishing whether the slowdown reflects better outcomes among anzu-cel patients, unexpectedly strong performance in the investigator-choice control group, differences in enrolled patient characteristics or a combination of these factors. Immatics N.V. has therefore modified the statistical plan without claiming that slower aggregate events constitute an efficacy signal.

The clinical evidence supporting optimism around anzu-cel instead comes from the earlier Phase 1b program. Updated results presented at the 2026 American Society of Clinical Oncology Annual Meeting showed a 56% confirmed objective response rate in metastatic melanoma, with median duration of response of 14.6 months. Median PFS was 6.1 months and median overall survival reached 16.2 months, while overall survival rates were 70% at 12 months and 46% at 24 months.

Those findings established meaningful antitumor activity and supported progression into SUPRAME, but they came from an earlier-stage, non-randomized dataset. The Phase 3 study must now demonstrate that anzu-cel creates a reproducible advantage when compared prospectively with contemporary investigator-selected therapy across hundreds of patients.

The enlarged trial could provide more confidence around that answer. A statistically positive PFS result supported by persuasive overall-survival trends would provide a much stronger foundation for commercialization than an impressive response rate generated in a relatively small early clinical cohort. A negative randomized result would correspondingly carry broader implications for Immatics N.V. because anzu-cel is expected to become the first commercial product from its PRAME franchise.

Immatics is spending ahead of a potential launch while its $448.2m liquidity cushions execution risk

The revised Phase 3 strategy arrives as development spending accelerates. Research and development expenses increased to $71.1 million during the second quarter from $51.4 million a year earlier, with Immatics N.V. attributing much of the increase to advancing clinical candidates, particularly SUPRAME. General and administrative expenses rose to $15.8 million from $14.6 million as the company increased activities associated with potential commercialization.

Collaboration revenue increased to $10.4 million from $5.4 million in the comparable 2025 quarter, while the quarterly net loss narrowed to $71.2 million from $80.1 million. The reduction in net loss partly reflected foreign-exchange effects in the prior-year period and higher collaboration revenue, while increased SUPRAME spending continued to weigh on operating results.

Liquidity declined by approximately $86.5 million from year-end to $448.2 million at June 30, although the balance was supported partly by $24.2 million of net proceeds from an at-the-market equity offering. Immatics N.V. nevertheless maintains that current resources should extend into 2028, giving the company financial coverage through the planned Phase 3 PFS readout, the anticipated 2027 BLA submission and substantial parts of its broader pipeline development.

That runway reduces one major source of biotechnology risk heading into a pivotal catalyst. Immatics N.V. does not currently appear dependent on raising a large amount of capital immediately before the anzu-cel readout simply to complete SUPRAME, while its liquidity gives management flexibility to prepare manufacturing and commercial infrastructure in parallel.

The investment is increasingly substantial, however. Net cash used in operating activities reached €102.5 million during the first six months of 2026, compared with €73.3 million in the year-earlier period. An unsuccessful Phase 3 result would therefore leave Immatics N.V. having invested heavily in late-stage development and commercialization preparation without its anticipated first marketed product.

A successful anzu-cel trial could validate a much larger PRAME franchise across solid tumors

SUPRAME carries significance beyond advanced melanoma because PRAME sits at the center of Immatics N.V.’s broader development strategy. The company says PRAME is expressed across more than 50 cancer types and is targeting the antigen through multiple therapeutic modalities, including anzu-cel, next-generation IMA203CD8 cell therapy and the off-the-shelf IMA402 TCR bispecific.

IMA203CD8 has already generated early clinical signals outside melanoma. Updated Phase 1 data in difficult-to-treat gynecologic cancers showed a 63% objective response rate and 50% confirmed response rate, including four complete responses. Synovial sarcoma patients produced a 67% objective response rate and 64% confirmed response rate, while additional findings across PRAME-positive tumors are expected at the 2026 European Society for Medical Oncology Congress.

The company is also expanding IMA402 into earlier treatment settings and combinations while testing a dual-bispecific approach using IMA402 with MAGEA4/8-directed IMA401 in squamous non-small cell lung cancer. First data from that combination are expected in 2027. Separately, Moderna dosed the first patient in July with mRNA-4200, a cancer antigen therapeutic candidate discovered through the companies’ collaboration, triggering a milestone payment to Immatics N.V.

A positive SUPRAME result would therefore offer more than an opportunity to file anzu-cel. It could provide the first late-stage randomized validation that Immatics N.V.’s PRAME targeting strategy can translate strong early response rates into a registration-quality outcome, potentially improving investor confidence across the rest of the portfolio.

IMTX stock remains subdued as investors resist treating slower Phase 3 events as hidden efficacy data

Immatics N.V. shares were trading around $8.98 on August 18, down approximately 2.9% from the previous close after ranging between $8.64 and $10.00. The company’s market capitalization stood near $925 million, meaning its $448.2 million liquidity position represents almost half of its current equity valuation.

The negative share movement suggests investors are taking a cautious view of the SUPRAME amendments rather than assuming that slower progression events indicate better anzu-cel efficacy. That interpretation is an inference from the market reaction, but it is consistent with the blinded nature of the trial and the absence of treatment-arm data.

The revised plan arguably makes the 2027 catalyst cleaner. There will no longer be an interim PFS result potentially producing an ambiguous market reaction before the definitive analysis, while the additional patients should improve the overall-survival dataset without delaying the primary endpoint. FDA feedback has also informed the planned modifications, reducing some uncertainty about how the agency views the evolving statistical approach.

Immatics N.V. has consequently concentrated more of the anzu-cel investment case into a single major readout. The company has enough liquidity to reach it, is strengthening the survival evidence around it and is already preparing for commercialization if it succeeds. What remains unknown is the one factor that ultimately matters most: whether the slower progression pattern observed across the blinded trial translates into a statistically and clinically meaningful advantage for anzu-cel when SUPRAME is finally unblinded in 2027.

Key takeaways on what the expanded anzu-cel Phase 3 trial means for Immatics

• Immatics N.V. is replacing planned interim and final SUPRAME PFS analyses with one definitive final analysis expected in the first half of 2027.
• The revised PFS analysis will retain 90% statistical power despite using a lower prespecified number of progression or death events.
• Approximately 90 additional patients will take SUPRAME enrollment to roughly 450 and strengthen statistical power for overall survival.
• The larger OS dataset is not expected to delay the final PFS readout or the planned 2027 BLA submission.
• Slower aggregate progression and death events cannot currently be attributed to anzu-cel because the randomized Phase 3 study remains blinded.
• Earlier Phase 1b anzu-cel data showed a 56% confirmed response rate and median response duration of 14.6 months in metastatic melanoma.
• Immatics N.V. held $448.2 million in cash and other financial assets at June 30 and projects its runway into 2028.
• Second-quarter research and development expenses rose to $71.1 million as SUPRAME and other clinical programs expanded.
• IMTX traded around $8.98 on August 18, down about 2.9%, with a market capitalization of approximately $925 million.
• The first-half 2027 SUPRAME PFS result now represents the clearest test of whether Immatics N.V. can convert its PRAME platform into its first regulatory filing and potential commercial product.